Last reviewed · How we verify
Suiny (ANAGLIPTIN)
At a glance
| Generic name | ANAGLIPTIN |
|---|---|
| Target | Dipeptidyl peptidase 4 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2012 |
Approved indications
- Diabetes mellitus type 2
Common side effects
Key clinical trials
- Glycemic Variability of Combination Therapies in T2DM (PHASE4)
- Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus (PHASE4)
- Korean Observational Study to Evaluate the Efficacy and Safety of Anagliptin Switching From Other DPP4is in type2 DM
- MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus (PHASE4)
- Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial (PHASE4)
- DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients With Congestive Heart Failure (PHASE4)
- Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors (PHASE4)
- Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |